Found: 30
Select item for more details and to access through your institution.
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 547, doi. 10.1016/j.clml.2022.02.005
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 557, doi. 10.1016/j.clml.2022.01.008
- By:
- Publication type:
- Article
Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 566, doi. 10.1016/j.clml.2022.03.003
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 569, doi. 10.1016/j.clml.2022.03.001
- By:
- Publication type:
- Article
Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 575, doi. 10.1016/j.clml.2022.02.008
- By:
- Publication type:
- Article
Response to Chlormethine/Mechlorethamine gel Maintenance Treatment Regimen in Patients With Mycosis Fungoides: A Single-center Retrospective Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 581, doi. 10.1016/j.clml.2022.02.002
- By:
- Publication type:
- Article
Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 589, doi. 10.1016/j.clml.2022.02.009
- By:
- Publication type:
- Article
Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 596, doi. 10.1016/j.clml.2022.02.007
- By:
- Publication type:
- Article
Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 601, doi. 10.1016/j.clml.2022.02.006
- By:
- Publication type:
- Article
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 608, doi. 10.1016/j.clml.2022.03.002
- By:
- Publication type:
- Article
Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 618, doi. 10.1016/j.clml.2022.03.004
- By:
- Publication type:
- Article
Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 626, doi. 10.1016/j.clml.2022.04.013
- By:
- Publication type:
- Article
Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 635, doi. 10.1016/j.clml.2022.04.014
- By:
- Publication type:
- Article
Clinico-hematological and Outcome Profile of Pediatric B-other-ALL and BCR::ABL1-like pre-B-ALL: An Integrated Genomic Study From North India.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e667, doi. 10.1016/j.clml.2022.03.007
- By:
- Publication type:
- Article
'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e680, doi. 10.1016/j.clml.2022.03.006
- By:
- Publication type:
- Article
Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e685, doi. 10.1016/j.clml.2022.03.005
- By:
- Publication type:
- Article
COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e691, doi. 10.1016/j.clml.2022.03.012
- By:
- Publication type:
- Article
Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e708, doi. 10.1016/j.clml.2022.03.014
- By:
- Publication type:
- Article
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e716, doi. 10.1016/j.clml.2022.03.013
- By:
- Publication type:
- Article
Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e730, doi. 10.1016/j.clml.2022.04.012
- By:
- Publication type:
- Article
Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e738, doi. 10.1016/j.clml.2022.04.006
- By:
- Publication type:
- Article
Indolent Lymphoproliferative T-Cell Disorders Associated With Gastrointestional Disease: Diagnostic Challenges and Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e745, doi. 10.1016/j.clml.2022.04.002
- By:
- Publication type:
- Article
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e751, doi. 10.1016/j.clml.2022.04.005
- By:
- Publication type:
- Article
Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e762, doi. 10.1016/j.clml.2022.04.004
- By:
- Publication type:
- Article
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e770, doi. 10.1016/j.clml.2022.04.003
- By:
- Publication type:
- Article
Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e777, doi. 10.1016/j.clml.2022.04.007
- By:
- Publication type:
- Article
Waldenstrom macroglobulinemia and simultaneous intravascular large B-cell lymphoma: Rare transformation or unhappy coincidence?
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e788, doi. 10.1016/j.clml.2022.04.008
- By:
- Publication type:
- Article
Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e792, doi. 10.1016/j.clml.2022.04.011
- By:
- Publication type:
- Article
Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e804, doi. 10.1016/j.clml.2022.04.010
- By:
- Publication type:
- Article
Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e815, doi. 10.1016/j.clml.2022.04.009
- By:
- Publication type:
- Article